Nguyen Michelle C, Lee Eliza J, Avery Robin K, Dioverti-Prono M Veronica, Shoham Shmuel, Tobian Aaron A R, Bloch Evan M, Gurakar Ahmet, Rizkalla Nicole A, Cameron Andrew M, King Elizabeth A, Ottmann Shane, Garonzik-Wang Jacqueline M, Wesson Russel N, Philosophe Benjamin
Division of Transplant Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Transplant Direct. 2021 Jul 8;7(8):e721. doi: 10.1097/TXD.0000000000001178. eCollection 2021 Aug.
Given the high community prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), transplant programs will encounter SARS-CoV-2 infections in living donors or recipients in the perioperative period. There is limited data on SARS-CoV-2 viremia and organotropism beyond the respiratory tract to inform the risk of transplant transmission of SARS-CoV-2. We report a case of a living donor liver transplant recipient who received a right lobe graft from a living donor with symptomatic PCR-confirmed SARS-CoV-2 infection 3 d following donation. The donor was successfully treated with remdesivir, dexamethasone, and coronavirus disease 2019 (COVID-19) convalescent plasma. No viral transmission was identified, and both donor and recipient had excellent postoperative outcomes.
鉴于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在社区中的高流行率，移植项目在围手术期会遇到活体供体或受体感染SARS-CoV-2的情况。关于SARS-CoV-2病毒血症及呼吸道以外的器官嗜性的数据有限，无法据此了解SARS-CoV-2移植传播的风险。我们报告了一例活体供肝移植受者的病例，该受者接受了一名活体供体的右叶移植肝，供体在捐献后3天出现症状，经PCR确诊感染SARS-CoV-2。供体接受了瑞德西韦、地塞米松和2019冠状病毒病（COVID-19）康复期血浆治疗，治疗成功。未发现病毒传播，供体和受体术后均获得良好预后。
